Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94


Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer.

Westin GF, Perez CA, Wang E, Glück S.

Int J Biol Markers. 2013 Sep 27;28(3):233-41. doi: 10.5301/JBM.5000040. Review.


mTOR inhibitors in advanced breast cancer: ready for prime time?

Martin LA, André F, Campone M, Bachelot T, Jerusalem G.

Cancer Treat Rev. 2013 Nov;39(7):742-52. doi: 10.1016/j.ctrv.2013.02.005. Epub 2013 Apr 1. Review.


Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.

Jordan NJ, Dutkowski CM, Barrow D, Mottram HJ, Hutcheson IR, Nicholson RI, Guichard SM, Gee JM.

Breast Cancer Res. 2014 Jan 23;16(1):R12. doi: 10.1186/bcr3604.


Everolimus: a new hope for patients with breast cancer.

Sendur MA, Zengin N, Aksoy S, Altundag K.

Curr Med Res Opin. 2014 Jan;30(1):75-87. doi: 10.1185/03007995.2013.846253. Epub 2013 Oct 14. Review.


Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.

Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, Lin L, Ellis MJ.

Breast Cancer Res. 2011 Mar 1;13(2):R21. doi: 10.1186/bcr2833.


Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.

Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E.

J Clin Oncol. 2012 Aug 1;30(22):2718-24. doi: 10.1200/JCO.2011.39.0708. Epub 2012 May 7.


Everolimus: targeted therapy on the horizon for the treatment of breast cancer.

Barnett CM.

Pharmacotherapy. 2012 Apr;32(4):383-96. doi: 10.1002/j.1875-9114.2012.01084.x. Review.


Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus.

Hadji P, Coleman R, Gnant M.

Crit Rev Oncol Hematol. 2013 Aug;87(2):101-11. doi: 10.1016/j.critrevonc.2013.05.015. Epub 2013 Jul 6. Review.


Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.

Martin LA, Pancholi S, Farmer I, Guest S, Ribas R, Weigel MT, Thornhill AM, Ghazoui Z, A'Hern R, Evans DB, Lane HA, Johnston SR, Dowsett M.

Breast Cancer Res. 2012 Oct 17;14(5):R132. doi: 10.1186/bcr3330.


In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.

Hurvitz SA, Kalous O, Conklin D, Desai AJ, Dering J, Anderson L, O'Brien NA, Kolarova T, Finn RS, Linnartz R, Chen D, Slamon DJ.

Breast Cancer Res Treat. 2015 Feb;149(3):669-80. doi: 10.1007/s10549-015-3282-x. Epub 2015 Feb 8.


The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.

Lauring J, Park BH, Wolff AC.

J Natl Compr Canc Netw. 2013 Jun 1;11(6):670-8. Review.


The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer.

Gnant M.

Curr Oncol Rep. 2013 Feb;15(1):14-23. doi: 10.1007/s11912-012-0277-1. Review.


[Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option].

Gilabert M, Launay S, Gonçalves A.

Bull Cancer. 2014 Mar;101(3):325-33. doi: 10.1684/bdc.2014.1910. Review. French.


PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.

Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Wesseling J, Muris JJ, Berns EM, Vermorken JB, van Diest PJ, Linn SC.

Breast Cancer Res. 2014 Jan 27;16(1):R13. doi: 10.1186/bcr3606.


A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.

Massarweh S, Romond E, Black EP, Van Meter E, Shelton B, Kadamyan-Melkumian V, Stevens M, Elledge R.

Breast Cancer Res Treat. 2014 Jan;143(2):325-32. doi: 10.1007/s10549-013-2810-9. Epub 2013 Dec 11. Erratum in: Breast Cancer Res Treat. 2015 Jan;149(2):565.


A systematic review of dual targeting in HER2-positive breast cancer.

Kümler I, Tuxen MK, Nielsen DL.

Cancer Treat Rev. 2014 Mar;40(2):259-70. doi: 10.1016/j.ctrv.2013.09.002. Epub 2013 Sep 11. Review.


Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer.

Ng VC, Johnson JJ, Cuellar S.

J Oncol Pharm Pract. 2015 Dec;21(6):433-42. doi: 10.1177/1078155214540732. Epub 2014 Jun 25. Review.


Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nuñez R, Hortobagyi GN, Yu D, Esteva FJ.

J Clin Oncol. 2011 Aug 10;29(23):3126-32. doi: 10.1200/JCO.2010.32.2321. Epub 2011 Jul 5.


Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN.

N Engl J Med. 2012 Feb 9;366(6):520-9. doi: 10.1056/NEJMoa1109653. Epub 2011 Dec 7.

Supplemental Content

Support Center